The Dutch Health Council Report on palliative chemotherapy; possible confusion of ideas;Het Gezondheidsraadrapport 'Palliatieve chemotherapie'; risico van begripsverwarring

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 14, 2004, Pages 651-654

  Verweij, J ^a   De Mulder, P H M ^b   Pinedo, H M ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MEDICAL PROFESSION; MEDICAL RESEARCH; NETHERLANDS; PATIENT CARE; POLITICS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; PALLIATIVE CARE; PRACTICE GUIDELINES; QUALITY OF LIFE;

EID: 1842418614     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Gezondheidsraad. Palliatieve chemotherapie. Publicatienr 2003/18. Den Haag: Gezondheidsraad; 2003.
2. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-60.
3. Koedoot CG, Haan RJ de, Stiggelbout AM, Stalmeier PFM, Graeff A de, Bakker PJ, et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. Br J Cancer 2003;89:2219-26.
4. Stiggelbout AM, Haes JC de. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 2001;19: 220-30.
5. Glabbeke M van, Oosterom AT van, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-7.
6. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
7. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. Br J Cancer 2000;83: 447-53.
8. Smith TJ, Hillner BE, Densch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:1460-74.
9. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6.
10. Mathijssen RH, Verweij J, Bruijn P de, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9.